Atrial fibrillation, with three to four percent of the population being affected and a steadily growing number of patients, is not only the most common cardiac arrhythmia worldwide but also a major cause of thromboembolic events. Currently available treatment options show high recurrence rates and low efficiency. Due to the limited understanding of pathophysiological mechanisms underlying atrial cardiomyopathy, available therapies are still insufficient. Therefore, the purpose of the professorship for "Atrial Arrhythmopathy" will be uncovering molecular and cellular electrophysiological causes resulting in the development of atrial cardiomyopathy. Based on the identification of essential pathophysiological mechanisms, new therapeutic approaches against atrial fibrillation shall be established.

Here you can find further information.